|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.22 HKD | -5.05% |
|
-0.21% | -32.94% |
| 06-29 | Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI | DJ |
| 06-24 | China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says | RE |
| Market Cap | 103B 119B 15.14B 13.23B 12.21B 11.26B 21.21B 1,458B 21.68B 146B 57.4B 714B 56.87B 55.62B 2,458B | P/E 2026 * |
17.5x | P/E 2027 * | 14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 62.87B 72.72B 9.28B 8.11B 7.48B 6.89B 13B 893B 13.28B 89.41B 35.17B 437B 34.84B 34.07B 1,506B | EV / Sales 2026 * |
0.73x | EV / Sales 2027 * | 0.54x |
| Free-Float |
32.24% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: JD Health International Inc.
| 02-03 | Burghley Capital: JD Property Reapplies for HK IPO | AQ |
| 15/08/24 | JD com misses estimates quarterly sales | AQ |
| 16/08/23 | JD.com verslaat verwachtingen | AQ |
| 09/03/23 | JD.com lacks estimates | AQ |
| 01/06/22 | JD Health International : Next Day Disclosure Return | PU |
| 1 day | -5.05% | ||
| 1 week | -0.21% | ||
| Current month | +13.34% | ||
| 1 month | +6.04% | ||
| 3 months | -23.19% | ||
| 6 months | -44.61% | ||
| Current year | -32.94% |
| 1 week | 34.72 |  | 39.7 |
| 1 month | 31.84 | | 39.7 |
| Current year | 31.84 | | 71.7 |
| 1 year | 31.84 | | 71.7 |
| 3 years | 19.48 | | 71.7 |
| 5 years | 19.48 | | 104.8 |
| 10 years | 19.48 | | 198.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dong Cao
CEO | Chief Executive Officer | 50 | 29/09/2025 |
Deng Hui
DFI | Director of Finance/CFO | 40 | 11/05/2023 |
Ming King Chiu
SEC | Corporate Secretary | 49 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Qiang Dong Liu
CHM | Chairman | 53 | 14/09/2020 |
Xing Yao Chen
BRD | Director/Board Member | 52 | - |
Ling Li
BRD | Director/Board Member | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/5/26 | Other | Company | 64,215,503 | 2.0000% | ||
| 31/3/26 | Other | Director | 2,842 | 0.0001% | ||
| 13/10/25 | Other | Director | 3,000 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.05% | -0.21% | -21.97% | -28.22% | 15.14B | |
| -3.17% | -3.17% | -28.51% | -32.80% | 6.93B | |
| +2.53% | +4.48% | -20.28% | -4.43% | 6.13B | |
| -2.80% | +3.58% | -12.04% | -30.87% | 3.73B | |
| +2.36% | +1.93% | -38.19% | -10.65% | 3.25B | |
| -0.66% | -1.69% | -30.87% | -50.25% | 3.15B | |
| -3.53% | +5.21% | +9.30% | -30.97% | 3.12B | |
| +0.37% | -1.07% | +99.80% | - | 2.57B | |
| +0.98% | +3.41% | -18.38% | -1.49% | 2.53B | |
| -0.92% | -1.23% | +0.62% | +35.92% | 1.67B | |
| Average | -0.99% | +0.86% | -6.05% | -17.08% | 4.82B | |
| Weighted average by Cap. | -2.01% | +0.57% | -14.13% | -22.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 86.62B 100B 12.78B 11.17B 10.31B 9.5B 17.9B 1,231B 18.3B 123B 48.45B 603B 47.99B 46.94B 2,075B | 99.99B 116B 14.75B 12.89B 11.9B 10.96B 20.67B 1,421B 21.13B 142B 55.92B 696B 55.4B 54.18B 2,395B |
| Net income | 5.82B 6.74B 859M 751M 693M 639M 1.2B 82.76B 1.23B 8.28B 3.26B 40.53B 3.23B 3.16B 140B | 7.06B 8.17B 1.04B 911M 841M 775M 1.46B 100B 1.49B 10.05B 3.95B 49.16B 3.91B 3.83B 169B |
| Net Debt | -39.76B -45.99B -5.87B -5.13B -4.73B -4.36B -8.22B -565B -8.4B -56.54B -22.24B -277B -22.03B -21.55B -952B | -48.59B -56.21B -7.17B -6.27B -5.78B -5.33B -10.04B -690B -10.27B -69.1B -27.18B -338B -26.92B -26.33B -1,164B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | HK$37.22 | -5.05% | 7,559,184 |
| 16/07/26 | HK$39.20 | +4.48% | 14,531,390 |
| 15/07/26 | HK$37.52 | +1.52% | 10,038,594 |
| 14/07/26 | HK$36.96 | +0.71% | 19,318,220 |
| 13/07/26 | HK$36.70 | -1.61% | 10,954,031 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6618 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition